Ursolic acid restores sensitivity to gemcitabine through the RAGE/NF-κB/MDR1 axis in pancreatic cancer cells and in a mouse xenograft model

Gemcitabine (GEM) is a first-line drug for pancreatic cancer therapy, but GEM resistance is easily developed in patients. Growing evidence suggests that cancer chemoprevention and suppression are highly associated with dietary phytochemical and microbiota composition. Ursolic acid (UA) has anti-infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zih-Ying, Chen, Sheng-Yi, Weng, Ming-Hong, Yen, Gow-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Food and Drug Administration 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261828/
https://www.ncbi.nlm.nih.gov/pubmed/35696208
http://dx.doi.org/10.38212/2224-6614.3346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261828/
https://www.ncbi.nlm.nih.gov/pubmed/35696208
http://dx.doi.org/10.38212/2224-6614.3346

Ejemplares similares